ǰÑÔ
ÌÇÄò²¡(diabetes)ÊÇÒ»ÖÖÒòÌåÄÚÒȵºËؾø¶Ô»òÕßÏà¶Ôȱ·¦Ëùµ¼ÖµÄһϵÁÐÁÙ´²×ÛºÏÕ÷£¬ÓëÒÅ´«»ùÒòÓÐןÜÊÇÇ×½üµÄ¹ØÁª¡£ÓÕ·¢ÌÇÄò²¡ÒòËØºÜÖØ´ó£¬ÔÚ´ó×ÚÈËȺÖÐÑо¿ÆÊÎöÕâЩÒòËØÊ®·ÖÄÑÌ⣬Òò´Ë£¬Ñо¿Ä³Ð©¶¯ÎïÖÖϵÌÇÄò²¡±¬·¢µÄ°Ù·ÖÂʼ°ÇéÐÎÒòËØ£¨Ñ¬È¾¡¢¶¾ËØ¡¢Òûʳ¼°Ò©ÎïµÈ£©¶ÔÓÕ·¢¶¯ÎïÌÇÄò²¡¼°Ä³Ð©²¢·¢Ö¢µÄÓ°Ï죬¿ÉΪ·ÀÖÎÈËÀàÌÇÄò²¡ÌṩÖ÷ÒªÏßË÷¡£¶ø¿¹ÌÇÄò²¡ÐÂÒ©µÄÑо¿£¬Ò²ÐëÏÈÊÔÓÃÓÚÌÇÄò²¡¶¯ÎÒÔÆÀ¼ÛÒ©ÎïµÄÁÆÐ§¼°Çå¾²ÐÔ¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
2ÐÍÌÇÄò²¡ÊǶà»ùÒòÒÅ´«£¬ÓÐÐí¶à»úÖÆ¼ÓÈë·¢²¡¡£ÎªÆÊÎöijһµ¥¸ö»ùÒòÔÚ2ÐÍÌÇÄò²¡·¢²¡ÖеÄ×÷Ó㬿ÉÓûùÒòÇóý»ò»ùÒò¹ý±í´ïµÈÊֶθ´ÖƳöһϵÁÐ2ÐÍÌÇÄò²¡¶¯ÎïÄ£×Ó¡£
1.GK/IRS-1Ë«»ùÒòÇóýСÊó ½«Ð¡ÊóÆÏÌÑÌǼ¤Ã¸»ùÒòÍâÏÔ×ÓÓÃÐÂÃ¹ËØ¶Ô¿¹(neo-mycin resistance)»ùÒòÈ¡´úÖÆ³ÉÄ¿µÄÔØÌåÔÓºÏÈëÕý³£Ð¡Êó£¬ÖƵÃGK-/-СÊó¡£IRS-1-/-СÊóÌåÏÖΪÒȵºËضԿ¹£¬µ«ÓÉÓÚβϸ°û´ú³¥ÐÔÔöÉú£¬ÒȵºËØÉøÍ¸Ôö¶à£¬ÌÇÄÍÁ¿Õý³£¡£βϸ°ûÌØÒìGK±í´ï½µµÍµÄСÊó£¬ÏÔʾÇá¶ÈÌÇÄÍÁ¿Òì³£¡£Á½ÕßÔÓ½»±¬·¢µÄGK/IRS-1Ë«»ùÒòÇóýСÊó£¬ÌÇÄÍÁ¿¼õÍË¡¢¸Îϸ°ûºÍÒȵºβϸ°ûÆÏÌÑÌÇÃô¸ÐÐÔµÍÏ£¬ÌåÏÖ2ÐÍÌÇÄò²¡Ö¢×´¡£
2.IR+/-/IRS-1+/-Ë«»ùÒòÇóýÔÓºÏÌåСÊó IR+/-ºÍIRS-1+/-µ¥¸ö»ùÒòÇóýÔÓºÏÌåСÊóÎÞÏÔ×ÅÁÙ´²Ö¢×´¡£µ«IR+/-/IRS-1+/Ë«»ùÒòÇóýÔÓºÏÌåСÊó4~6¸öÔºó40%СÊ󱬷¢ÏÔÐÔÌÇÄò²¡£¬°éÓиßÒȵºËØÑªÖ¢ºÍÒȵºβϸ°ûÔöÉú£¬´Ó¶øÖƵÃ2ÐÍÌÇÄò²¡¶¯ÎïÄ£×Ó£¬±£´æÏÔ×ÅÒȵºËضԿ¹¡£
3.MKRת»ùÒòСÊó ¹Ç÷À¼¡ÒȵºËØÑùÉú³¤Òò×Ó-1(IGF-1)ÊÜÌåµÄ¹¦Ð§È±Ê§µÄMKRСÊó£¬ÓÉÓÚÔÓ½»ÐÍÊÜÌåµÄÐγɣ¬ÌåÏÖΪÒȵºËØÊÜÌåµÄ¹¦Ð§È±Ê§¡£MKRСÊóÔÚ³öÉú3ÖÜ×îÏÈ£¬·ºÆðÏÔÖøÑªÌÇÉý¸ß£¬5Öܺó¼´ÌåÏÖ³öÏÔÖøµÄÒȵºËضԿ¹¡¢¸ßѪÌÇ¡¢Òȵºβϸ°û¹¦Ð§ÔÓÂÒ¼°Ö¬´úлÔÓÂҵȡ£
¡¾Ä£×ÓÌØµã¡¿£º
GK+/-/IRS-1-/-СÊóÆÏÌÑÌÇÌÇÄÍÁ¿¼õÍË£¬Òȵºβϸ°ûºÍ¸Îϸ°ûÆÏÌÑÌÇÃô¸ÐÐÔ½µµÍ£¬ÓôËÀàÄ£×Ó×÷ÌÇÄò²¡¿ÆÑпÆÑ§ÐÔÇ¿¡£GK+/-/IRS-1-/-Ë«»ùÒòÇóýÔÓºÏÌåСÊóΪ2ÐÍÌÇÄò²¡¶¯ÎïÄ£×Ó¡£MKRת»ùÒòСÊóÄ£×Ó·¢²¡¿ì¡¢Ó¦ÓüòÆÓ¡¢´æ»îÂʸߡ£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
GK/IRS-1Ë«»ùÒòÇóýСÊóÓëÈËÇà´ºÍíÆÚÌÇÄò²¡(maturity onset diabetes of the young,MODY)ÏàËÆ£¬¿É×÷ΪMODY¶¯ÎïÄ£×Ó¡£IR+/-/IRS-1+/-Ë«»ùÒòÇóýÔÓºÏÌåСÊó¼°MKRת»ùÒòСÊó¾ù¿ÉÓÃÓÚ2ÐÍÌÇÄò²¡µÄ·¢²¡»úÖÆ¼°·ÀÖÎÒªÁìµÄÑо¿¡£
²Î¿¼ÎÄÏ×£º
1.Àî´ÏÈ»£¬ÓÎÑ©¸¦£¬½¯½¨¶«. ÌÇÄò²¡¶¯ÎïÄ£×Ó¼°Ñо¿Ï£Íû. Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾£¬2005,15 (1):59-63
2.ÕÅÓñÁ죬Ëﳤò«£®2ÐÍÌÇÄò²¡¶¯ÎïÄ£×ÓµÄÑо¿Ï£Íû£®ÊÊÓÃÌÇÄò²¡ÔÓÖ¾£¬2011,7(4):7-9
3.ÕÅ´«²Ö£¬ÁõÎÀÅô£¬¶Å½£¬µÈ£®¸ÄÁ¼ËÄÑõà×ष¨ÖÆ×÷ÌÇÄò²¡¶¯ÎïÄ£×Ó£®ÊÊÓÃҽѧÔÓÖ¾£¬2007,23 (5):623-624
4.³Â½¼Àö£¬ÑîÓ¨£®ÌÇÄò²¡ÊóÄ£×ÓÑо¿ÐÂÏ£Íû£®À¥Ã÷ҽѧԺѧ±¨£¬2012,2:144-146
5.ÕžùÌÏÖ´úÒ©ÀíʵÑéÒªÁì±±¾©£º±±¾©Ò½¿Æ´óѧÖйúкÍÒ½¿Æ´óѧÍŽá³öÊéÉ磬1998
6.ÐìÊåÔÆ£¬±åÈç奣¬³ÂÐÞÒ©ÀíʵÑéÒªÁìѧ£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬2005
7.¸ßºìÀò£¬Áõ·½ÓÀ£¬ÏÄ×÷Àí. ʵÑéÐÔÌÇÄò²¡¶¯ÎïÄ£×ÓµÄÀíÂÛÑо¿ÓëÓ¦Óã®ÖйúÁÙ´²¿µ¸´£¬2005,9 (3):210-212
8.Åí·¼£¬ÑîÔ¶»ª. ʵÑéÐÔÌÇÄò²¡¶¯ÎïÄ£×ÓÖÆ±¸¼°Ö¸±ê²â¶¨ÆÀ¼Û. ´óÀíѧԺѧ±¨£¬2003, 2(1): 1-3
9.Aubert R, Herzog J, Camus MC, et al. Description of a new model of genetic obesity: the dbPas mouse. J Nutr, 1985, 115 (3):327-333
10.Hagenieldt-Johansson KA,Herrera PL,Wang H,et al. Beta-cell-targeted expression of a dominant-negative hepatocyte nuclear factor- I alpha induces a maturityonset diabetes of the young (MODY)3-like phenotype in transgenic mice. Endocrinology, 2001, 142 (12):5311- 5320
11.Hummel KP, Coleman DL, Lane PW. The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL- 6J strains. Biochem Genet, 1972, 7 (1):1-13
12.Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest, 2000, 106(4):459-465